EX-99.1 2 tm2622452d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone, combined with expected product revenue and future tranche from Oberland facility, expected to extend cash runway into the second half of 2027 Company to host a conference call and webcast today at 4:30 p.m. ET BOSTON--(BUSINESS WIRE) - Aug. 6, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Verastem, Inc.
VSTMNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On August 6, 2026, Verastem, Inc. (the “Company”) issued a press release reporting financial results for the quarter ended June 30, 2026, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 2.02.
Company context
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding Verastem, Inc.Aug 14, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Regulation FD DisclosureAug 7, 2026
- 10-Q filingAug 6, 2026
- SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Verastem, Inc.Jul 31, 2026
- 4 filingJun 24, 2026